Antioxidant treatment for heart failure: friend or foe

Mandy J. Thomson, Michael P. Frenneaux, J. C. Kaski

Research output: Contribution to journalLiterature review

14 Citations (Scopus)

Abstract

Increasing studies demonstrate a pivotal role for oxidant stress in the pathophysiology of heart failure (HF). Recent meta-analyses also reveal the potential pitfall of a mono-dimensional antioxidant approach. This review article summarizes the main biological pathways involved in oxidant stress and HF, the possible deleterious nature of certain antioxidant monotherapy and proposes potential antioxidant strategies necessary to challenge specific HF aetiology and progression.

Oxidant stress is well established in the aetiology of cardiovascular disease (CVD) and increasingly implicated in congestive heart failure (CHF). Human and animal models of CHF demonstrate enhanced reactive oxygen species (ROS) production, reduced antioxidant reserve and ROS-mediated cardiac injury. Similarly, various ‘antioxidant’ agents used in the treatment of CHF appear to confer cardio-protective benefits. In contrast, recent meta-analyses have suggested a deleterious effect of vitamin E in heart failure (HF), warranting reappraisal of ‘antioxidant’ use in this context.

Original languageEnglish
Pages (from-to)305-310
Number of pages6
JournalQJM
Volume102
Issue number5
Early online date18 Dec 2008
DOIs
Publication statusPublished - May 2009

Keywords

  • nitric-oxide synthase
  • tumor-necrosis-factor
  • vitamin-E supplementation
  • failing human heart
  • myocardial-infarction
  • oxidative stress
  • dilated cardiomyopathy
  • cardiovascular events
  • NADPH oxidase
  • factor-alpha

Cite this

Thomson, M. J., Frenneaux, M. P., & Kaski, J. C. (2009). Antioxidant treatment for heart failure: friend or foe. QJM, 102(5), 305-310. https://doi.org/10.1093/qjmed/hcn160